Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction

Launched by BEIJING LUHE HOSPITAL · Apr 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called evolocumab, which lowers cholesterol levels, on patients who have had a type of heart attack known as ST-segment elevation myocardial infarction (STEMI). The researchers want to see if giving this medication before a procedure called percutaneous coronary intervention (PCI), which opens blocked arteries, can improve outcomes for these patients. The trial will look at how this treatment affects cholesterol levels, inflammation in the body, heart damage, and short-term recovery after the heart attack.

To participate in this trial, patients must be between 18 and 80 years old, have experienced chest pain for at least 30 minutes, and show specific changes on their heart monitoring test within 24 hours of the heart attack. They must also agree to take part by signing an informed consent form. However, individuals with certain serious health issues, such as severe kidney or liver problems, or those who are pregnant or breastfeeding, cannot join the study. Participants can expect close monitoring and care as the researchers gather important information to help improve treatment options for future patients with similar heart conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients are selected from the Cardiology Department of Beijing Luhe Hospital and have undergone direct PCI treatment for STEMI.
• * STEMI patients must meet the following criteria:
• • 1. Chest pain duration ≥ 30 minutes, with ST-segment elevation ≥ 0.1 mV in adjacent two leads on the electrocardiogram.
• • 2. Onset within 24 hours.
• • 3. Aged between 18 and 80 years.
• • 4. Signed informed consent form.
• Exclusion Criteria:
• • Hemodynamically unstable or Killip grade ≥ 2.
• • Severe renal insufficiency: Glomerular filtration rate \< 30 ml/min/1.73m\^2.
• • Active liver disease or liver dysfunction: AST or ALT levels \> 3 times the upper limit of normal.
• • Known allergy to any drug used in the study.
• • Previous or planned use of PCSK9 inhibitors.
• • Suspected stress cardiomyopathy or acute pericarditis.
• • Malignant tumors requiring treatment or other severe systemic diseases.
• • Pregnancy or breastfeeding